Instituto Ramón y Cajal de Investigación Sanitaria

Logo IRYCIS

Contact information

Instituto Ramón y Cajal de Investigación Sanitaria
Emma González
Ctra.Colmenar Viejo Km 9,100, 28034
Madrid
Madrid
913369133
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
      • Biomarkers
      • Medical devices
      • Drug development
      • Drug discovery
      • Screening
      • Gene Therapy
      • Vaccines
    • Therapeutic areas
      • Analgesia & Pain
      • Dermatology
      • Musculoskeletal system
      • Cardiovascular diseases and circulatory system
      • Genetic and rare diseases
      • Infectious diseases
      • Inflammatory diseases
      • Gynaecology and obstetrics
      • Immunology
      • Odontology
      • Ophtalmology and optometry
      • Oncology
      • Blood and lymphatic system
      • Digestive system and hepatology
      • Kidney and genitourinary system
      • Central nervous system
      • Respiratory and pulmonary system
      • Metabolic disorders / Endocrinology
  • D. Services
    • R&D services
      • Bioinformatics
      • Genomics
      • Metabolomics
      • Proteomics

The Ramon y Cajal Institute for Biohealth Research (IRYCIS) is a large multidisciplinary organization which integrates scientific and clinical researchers, physicians, and other technical staff from the hospital.

The IRYCIS' aim is to join the knowledge, resources and initiatives of their members, leading to real advances for disease's prevention and treatment, and the improvement of diagnostics technologies.

Products and services

The research groups of IRYCIS are classified in four major areas:

  • Neuroscience and Sense Organs
  • Microbiology, Immunology and Infection
  • Systemic Patology and Cancer
  • Clinical Epidemiology

The Institute led by its Innovation Unit (IU), aims to transfer the research and innovation beyond its walls, and to participate in an european open innovation context contributing to improve patient care and provide new solutions for unmet medical needs.

Areas of interest for future collaborations

IRYCIS has a portfolio consisting of patents to out license, services to offer and research projects looking for industrial collaboration. The Institute also wants to open the door to new Horizon 2020 collaborations.

Biotech Sanitaria

Drugs National Companies
Product / Service Type Therapeutic area Development phase
New compound for the treatment of isquemical stroke Biodrugs/ Drugs Sistema nervioso central R&D
New aptamers for the treatment of stroke Biodrugs/ Drugs Sistema nervioso central P II
Research Platforms
Product / Service Type Development phase
miRNA platform Screening/Drug Discovery Clinical Validation
Diagnostics and Personalised Medicine
Product / Service Type Therapeutic area Development phase
Biomarkers to identify ocrelizumab good drug responders in patients with PP multiple sclerosis Biomarkers Inmunología, Sistema nervioso central Clinical Validation
Biomarkers to identify IFN-BETA drug responders in patients with multiple sclerosis Biomarkers, Diagnostic Inmunología, Sistema nervioso central Registration
New biomarkers to predict secundary autoimmunity before the treatment with alemtuzumab in MS Biomarkers Inmunología, Sistema nervioso central Registration
Noverl biomarkers of acute kidney injury based on miRNAs Biomarkers, Diagnostic Sistema genitourinario y riñón Clinical Validation
Predictive biomarkers of response after neoadjuvant therapy in locally advanced rectal adenocarcinoma Biomarkers Oncología R&D
New aptamers for diagnosis of COVID19 Biomarkers, Diagnostic Inmunología R&D
New biomarkers to identify good responders to cis-platinum in lug cancer Biomarkers, Diagnostic Oncología Preclinical
miRNA 127 agents for use in the treatment of renal fibrosis Biomarkers, Diagnostic Sistema genitourinario y riñón Clinical Validation
New aptamers against HCV Biomarkers, Diagnostic Enfermedades infecciosas Preclinical
Diagnosis of melanoma with support of AI Diagnostic Dermatología Registration
Diagnosis of osteoporosis with support of AI Diagnostic Desórdenes musculoesqueléticos R&D
Aptamers against MNK1 for the treatment of breast cancer Oncología Preclinical
Biomarkers to identify the response to OIT of children allergics to caw milk proteins Biomarkers, Diagnostic Inmunología Clinical Validation
Other Technologies
Product / Service Therapeutic area Development phase
Telemedicine platforms Oncología Preclinical
MAPAC2 Registration
PREVEMAMA Oncología Registration
CereVRAL Sistema nervioso central Registration